

KING PHARMACEUTICALS INC  
Form 8-K  
December 10, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): December 10, 2008 (December 4, 2008)  
King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in charter)

Tennessee

001-15875

54-1684963

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

501 Fifth Street, Bristol, Tennessee

37620

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (423) 989-8000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 4, 2008, the Compensation and Human Resources Committee of the Board of Directors of King Pharmaceuticals, Inc. approved base salary increases for certain of King's executive officers, effective December 29, 2008, in recognition of their contributions to King during 2008. These changes are as follows:

<b>Officer</b>	<b>Current Salary</b>	<b>Adjusted Salary</b>	<b>Difference</b>
Joseph Squicciarino <i>Chief Financial Officer</i>	\$552,000	\$600,000	\$48,000
Stephen J. Andrzejewski <i>Chief Commercial Officer</i>	\$411,000	\$427,500	\$16,500
Eric J. Bruce <i>Chief Technical Operations Officer</i>	\$411,000	\$431,500	\$20,500
James W. Elrod <i>General Counsel and Secretary</i>	\$431,500	\$468,000	\$36,500

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 10, 2008

KING PHARMACEUTICALS, INC.

By: /s/ Brian A. Markison  
Brian A. Markison  
President and Chief Executive Officer